Holen Sie sich die Stockscreener-App
34.46
1.56%
-0.54
Schlusskurs vom Vortag:
$35.00
Offen:
$35.15
24-Stunden-Volumen:
253.79K
Relative Volume:
0.55
Marktkapitalisierung:
$1.09B
Einnahmen:
$780.57M
Nettoeinkommen (Verlust:
$62.87M
KGV:
20.07
EPS:
1.7171
Netto-Cashflow:
$327.58M
1W Leistung:
-7.61%
1M Leistung:
-24.76%
6M Leistung:
-7.68%
1J Leistung:
+18.40%
1-Tages-Spanne:
$34.39
$35.27
1-Wochen-Bereich:
$34.27
$37.76
52-Wochen-Spanne:
$23.23
$50.79
Collegium Pharmaceutical Inc Stock (COLL) Company Profile
Firmenname
Collegium Pharmaceutical Inc
Sektor
Telefon
781-713-3699
Adresse
100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA
Compare COLL vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COLL
Collegium Pharmaceutical Inc
|
34.46 | 1.11B | 780.57M | 62.87M | 327.58M | 1.7171 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.75 | 56.14B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.50 | 48.74B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.04 | 44.85B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.41 | 34.12B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
538.05 | 23.35B | 3.13B | 1.27B | 1.12B | 26.39 |
Collegium Pharmaceutical Inc Stock (COLL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-01-10 | Hochstufung | Needham | Hold → Buy |
| 2024-07-30 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-06-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-05-10 | Herabstufung | Needham | Buy → Hold |
| 2024-05-10 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-01-04 | Herabstufung | Jefferies | Buy → Hold |
| 2023-08-25 | Bestätigt | Needham | Buy |
| 2023-05-02 | Fortgesetzt | Jefferies | Buy |
| 2022-08-08 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-02-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-14 | Eingeleitet | BWS Financial | Sell |
| 2020-05-27 | Eingeleitet | Guggenheim | Neutral |
| 2020-02-19 | Fortgesetzt | Jefferies | Buy |
| 2019-10-30 | Bestätigt | Needham | Buy |
| 2019-05-03 | Fortgesetzt | H.C. Wainwright | Buy |
| 2019-04-12 | Fortgesetzt | Janney | Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2019-01-16 | Bestätigt | Needham | Buy |
| 2018-03-08 | Bestätigt | H.C. Wainwright | Buy |
| 2018-02-07 | Bestätigt | Needham | Buy |
| 2017-12-05 | Bestätigt | Needham | Buy |
| 2017-09-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-05-11 | Bestätigt | Needham | Buy |
| 2016-09-13 | Eingeleitet | Gabelli & Co | Buy |
| 2015-06-01 | Eingeleitet | Jefferies | Buy |
| 2015-06-01 | Eingeleitet | Needham | Buy |
| 2015-06-01 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Collegium Pharmaceutical Inc Aktie (COLL) Neueste Nachrichten
Insider Sell: David Dieter Sells Shares of Collegium Pharmaceuti - GuruFocus
Risk Recap: What is the dividend yield of Collegium Pharmaceutical IncIndex Update & Weekly Setup with ROI Potential - baoquankhu1.vn
Collegium Pharmaceutical at Barclays Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
WINTON GROUP Ltd Purchases Shares of 65,345 Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Victory Capital Management Inc. Cuts Stock Position in Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Collegium Pharmaceutical (COLL) Surged Following Record Quarterly Results - Yahoo Finance
Jefferies Financial Group Inc. Takes $4.43 Million Position in Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Assessing Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Weakness - simplywall.st
Market Catalysts: Can Collegium Pharmaceutical Inc be the next market leaderMarket Movers & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Collegium Pharmaceutical, Inc. (COLL) gains momentum on Jornay PM, Truist highlights robust pain portfolio - MSN
Dow Update: Will Collegium Pharmaceutical Inc benefit from green energy policiesTrade Volume Report & Smart Money Movement Alerts - baoquankhu1.vn
(COLL) Volatility Zones as Tactical Triggers - Stock Traders Daily
Pharma News: Can Collegium Pharmaceutical Inc benefit from deglobalizationQuarterly Market Summary & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Citigroup Inc. Decreases Stock Holdings in Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Insider Sell: Scott Dreyer Sells 49,976 Shares of Collegium Phar - GuruFocus
Scott Dreyer Sells 49,976 Shares of Collegium Pharmaceutical (NASDAQ:COLL) Stock - MarketBeat
Collegium to Present New Real-World Data at PainConnect 2026 - The Manila Times
Quantbot Technologies LP Has $1.79 Million Position in Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Collegium enrolls Paris Hilton in Jornay PM push encouraging ADHD community to 'Embrace Your Sparkle' - Fierce Pharma
49,976 COLL shares flagged for sale (NASDAQ: COLL) - Stock Titan
Collegium, Paris Hilton announce ‘Embrace Your Sparkle’ campaign - TipRanks
Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community - ChartMill
Collegium Pharmaceutical Faces Weak Start with 8.74% Gap Down Amid Market Concerns - Markets Mojo
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Momentum Shift: Does Collegium Pharmaceutical Inc offer margin of safety2025 Pullback Review & Weekly High Return Stock Forecasts - baoquankhu1.vn
Can Collegium Pharmaceutical Inc be the next market leaderMarket Growth Report & Reliable Price Breakout Signals - baoquankhu1.vn
Collegium to Participate in Upcoming Investor Conferences - The Manila Times
Collegium Pharmaceutical plans four Miami investor events in March - Stock Titan
Aug EndMonth: What are analysts price targets for Collegium Pharmaceutical IncShort Setup & Growth Oriented Trading Recommendations - baoquankhu1.vn
Collegium Pharmaceutical, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:COLL) 2026-03-01 - Seeking Alpha
A Look At Collegium Pharmaceutical (COLL) Valuation After Mixed Q4 2025 Results And Updated 2026 Guidance - simplywall.st
Collegium Pharmaceutical (NASDAQ:COLL) Lowered to Buy Rating by Wall Street Zen - MarketBeat
Why Collegium Pharmaceutical (COLL) Is Down 7.4% After Reaffirming 2026 Revenue Guidance Despite Earnings Miss - Yahoo Finance
Why Collegium Pharmaceutical (COLL) Stock Is Trading Lower Today - Finviz
Analysts Have Conflicting Sentiments on These Healthcare Companies: Collegium Pharmaceutical (COLL) and Intellia Therapeutics (NTLA) - The Globe and Mail
Relative Strength Alert For Collegium Pharmaceutical - Nasdaq
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q4 2025 Earnings Call Transcript - Insider Monkey
Collegium (COLL) Q4 2025 Earnings Call Transcript - AOL.com
Collegium Pharmaceutical (COLL) Margin Compression To 8.1% Tests Bullish Profitability Narrative - simplywall.st
Collegium Pharmaceutical Earnings Call: Jornay Leads Growth - TipRanks
Collegium Pharmaceutical reports Q4 adjusted EPS $2.04, consensus $2.14 - TipRanks
Collegium Pharmaceutical (NASDAQ:COLL) Announces Quarterly Earnings Results, Misses Expectations By $0.16 EPS - MarketBeat
Collegium Pharmaceutical: Q4 Earnings Snapshot - theheraldreview.com
Collegium Pharmaceutical, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Deep Dive Into Collegium Pharmaceutical Stock: Analyst Perspectives (5 Ratings) - Benzinga
Collegium Pharmaceutical (NASDAQ:COLL) Price Target Lowered to $54.00 at Needham & Company LLC - MarketBeat
Collegium Pharmaceutical (COLL) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Miss Estimates - Nasdaq
Earnings call transcript: Collegium Pharmaceutical Q4 2025 misses EPS forecast - Investing.com Nigeria
Collegium Pharmaceutical (NASDAQ:COLL) Shares Gap Down on Disappointing Earnings - MarketBeat
Collegium Pharmaceutical Q4 Adjusted Earnings, Net Product Revenue Rise - marketscreener.com
Finanzdaten der Collegium Pharmaceutical Inc-Aktie (COLL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):